The utility of dynamic contrast-enhanced ultrasonography for evaluation of tumor viability in patients with metastatic colorectal cancer after chemotherapy

2023 Fiscal Year Final Research Report

• Project/Area Number: 19K07786
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 50020:Tumor diagnostics and therapeutics-related
• Research Institution: Hyogo Medical University
• Principal Investigator: Nakamura Ikuo 兵庫医科大学, 医学部, 准教授 (10625312)
• Co-Investigator(Kenkyū-buntansha): 波多野 悦朗 兵庫医科大学, 医学部, 非常勤講師 (80359801) ; 藤元 治朗 兵庫医科大学, 医学部, 特別招聘教授 (90199373)
• Project Period (FY): 2019-04-01 – 2024-03-31
• Keywords: 転移性肝癌 / 化学療法 / 造影超音波検査

Outline of Final Research Achievements

We has been reporting that in hepatocellular carcinoma, contrast-enhanced ultrasound using microbubbles (sonazoids) can predict prognosis based on tumor enhancement patterns (presented at conferences and currently under journal submission). In assessing the efficacy of chemotherapy for metastatic liver cancer, tumor size is commonly used. However, in reality, the degree of tumor cell necrosis (viability) is more important than tumor size, and currently, there is no accurate test for determining tumor viability. Tumors undergo necrosis with chemotherapy, resulting in reduced nutrient vascularization and decreased inflow blood flow. Based on these factors, this study aims to elucidate the relationship between changes in tumor enhancement effects due to chemotherapy as observed in contrast-enhanced ultrasound and viability, and to develop a new method for determining tumor viability

Free Research Field

肝胆膵外科

Academic Significance and Societal Importance of the Research Achievements

現在、転移性肝癌の化学療法の効果判定のために腫瘍viabilityを正確に評価できる検査
は開発されていない。今回、簡便な造影超音波検査による腫瘍viability評価の有用性を明
らかにすることは非常に意義があると思われる。